JP2014509593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509593A5 JP2014509593A5 JP2013558187A JP2013558187A JP2014509593A5 JP 2014509593 A5 JP2014509593 A5 JP 2014509593A5 JP 2013558187 A JP2013558187 A JP 2013558187A JP 2013558187 A JP2013558187 A JP 2013558187A JP 2014509593 A5 JP2014509593 A5 JP 2014509593A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- erbb3
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452976P | 2011-03-15 | 2011-03-15 | |
| US201161452974P | 2011-03-15 | 2011-03-15 | |
| US61/452,974 | 2011-03-15 | ||
| US61/452,976 | 2011-03-15 | ||
| PCT/US2012/029292 WO2012125864A2 (en) | 2011-03-15 | 2012-03-15 | Overcoming resistance to erbb pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509593A JP2014509593A (ja) | 2014-04-21 |
| JP2014509593A5 true JP2014509593A5 (enExample) | 2014-06-19 |
Family
ID=45953230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558187A Withdrawn JP2014509593A (ja) | 2011-03-15 | 2012-03-15 | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150231238A1 (enExample) |
| EP (2) | EP2686015A2 (enExample) |
| JP (1) | JP2014509593A (enExample) |
| KR (1) | KR20140023921A (enExample) |
| CN (1) | CN103429262A (enExample) |
| AU (1) | AU2012229062A1 (enExample) |
| BR (1) | BR112013022887A2 (enExample) |
| CA (1) | CA2828043A1 (enExample) |
| EA (1) | EA201301025A1 (enExample) |
| IL (1) | IL228393A0 (enExample) |
| MX (1) | MX2013010444A (enExample) |
| SG (1) | SG192775A1 (enExample) |
| WO (1) | WO2012125864A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2012318541B2 (en) * | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| US9956276B2 (en) * | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2015048008A2 (en) * | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| EP3052129A2 (en) * | 2013-09-30 | 2016-08-10 | Daiichi Sankyo Company, Limited | Protein biomarker and uses thereof |
| WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| SMT202500020T1 (it) * | 2014-02-28 | 2025-03-12 | Merus Nv | Anticorpo che lega erbb-2 ed erbb-3 |
| EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| MX2016014862A (es) * | 2014-05-14 | 2017-02-27 | Hoffmann La Roche | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016038609A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| AU2016248329A1 (en) * | 2015-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| US11214774B2 (en) * | 2015-05-01 | 2022-01-04 | Andrew Man Chung Wo | PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017035482A1 (en) * | 2015-08-27 | 2017-03-02 | Merrimack Pharmaceuticals, Inc | Combination therapies for treatment of heregulin positive cancers |
| WO2017069628A2 (en) | 2015-10-23 | 2017-04-27 | Merus N.V. | Binding molecules that inhibit cancer growth |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| CN108697779B (zh) | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| US11780925B2 (en) | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
| US12195551B2 (en) | 2017-05-17 | 2025-01-14 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
| SI3665198T1 (sl) | 2017-08-09 | 2025-06-30 | Merus N.V. | Protitelesa, ki vežejo egfr in cmet |
| WO2019088348A1 (ko) * | 2017-11-06 | 2019-05-09 | 한국과학기술원 | Egfr 저해제 저항성 암 치료제 |
| JP7532514B2 (ja) * | 2019-10-24 | 2024-08-13 | メルス ナムローゼ フェンノートシャップ | Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 |
| CA3237844A1 (en) | 2021-11-15 | 2023-05-19 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| AR127893A1 (es) * | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| NZ597466A (en) | 2007-03-01 | 2013-08-30 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
| NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
| BRPI0911652A2 (pt) * | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| SG10201402742YA (en) * | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| WO2010127181A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| KR101862832B1 (ko) * | 2010-11-01 | 2018-05-30 | 심포젠 에이/에스 | Ｐａｎ―ｈｅｒ 항체 조성물 |
| CN103547598A (zh) * | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
-
2012
- 2012-03-15 JP JP2013558187A patent/JP2014509593A/ja not_active Withdrawn
- 2012-03-15 WO PCT/US2012/029292 patent/WO2012125864A2/en not_active Ceased
- 2012-03-15 US US14/004,848 patent/US20150231238A1/en not_active Abandoned
- 2012-03-15 EA EA201301025A patent/EA201301025A1/ru unknown
- 2012-03-15 CN CN201280011820XA patent/CN103429262A/zh active Pending
- 2012-03-15 EP EP12714108.3A patent/EP2686015A2/en not_active Withdrawn
- 2012-03-15 BR BR112013022887A patent/BR112013022887A2/pt not_active IP Right Cessation
- 2012-03-15 SG SG2013061791A patent/SG192775A1/en unknown
- 2012-03-15 AU AU2012229062A patent/AU2012229062A1/en not_active Abandoned
- 2012-03-15 MX MX2013010444A patent/MX2013010444A/es unknown
- 2012-03-15 KR KR1020137026522A patent/KR20140023921A/ko not_active Withdrawn
- 2012-03-15 CA CA2828043A patent/CA2828043A1/en not_active Abandoned
- 2012-03-15 EP EP14166702.2A patent/EP2815765A1/en not_active Withdrawn
-
2013
- 2013-09-12 IL IL228393A patent/IL228393A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522237A5 (enExample) | ||
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| JP2022526764A5 (enExample) | ||
| JP2024037894A5 (enExample) | ||
| JP2018052959A5 (enExample) | ||
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| JP2013537546A5 (enExample) | ||
| JP2015500828A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JP2016166203A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| HRP20170462T1 (hr) | Protutijela za epidermalni receptor 3 faktora rasta (her3) | |
| EP3603672A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2010523536A5 (enExample) | ||
| CA2872226A1 (en) | Humanized pan-her antibody compositions | |
| AU2013201584A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody | |
| US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| RU2012151889A (ru) | Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr | |
| WO2012154587A2 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| US20240398943A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof | |
| JP2024538148A5 (enExample) | ||
| JP2025509266A5 (enExample) | ||
| JP2017515843A5 (enExample) |